Non-Interventional Study (NIS) of Nivolumab With or Without Ipilimumab in Participants With Advanced Kidney Cancer
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
623actual
Sites
1
Country
France
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2018-01-21 | actual | When the study began enrolling |
| Primary completion | 2025-12-18 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-12-18 | actual | The whole study's end, after follow-up |
| First posted | 2018-03-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Renal Cell Carcinoma
- Renal Cell Cancer
- Adenocarcinoma Of Kidney
- Adenocarcinoma, Renal Cell
- Kidney Cancer
- Cancer of the Kidney
Primary outcome
what the primary-completion date above is the date OFOverall Survival (OS)
measured Up to 3 years
Publications
- PMID 38897136 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed